Stockreport

ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating [Seeking Alpha]

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF SPRY faces competitive threats from generics and upcoming alternatives, but patent litigation could delay generic Neffy entry until 2039. Neffy's needle-free, lower-c [Read more]